Evidence for metabolic cleavage of a PEGylated protein in vivo using multiple analytical methodologies

Molecular Pharmaceutics

Volumn 9, Issue 5, 2012, Pages 1291-1301

  Elliott, Victoria L ^a   Edge, George T ^a   Phelan, Marie M ^a   Lian, Lu Yun ^a   Webster, Rob ^b   Finn, Rory F ^c   Park, B Kevin ^a   Kitteringham, Neil R ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^c PFIZER INC   (United States)

Author keywords

insulin; NMR; PEGylation; pharmacokinetics; Western blotting

Indexed keywords

IMMUNOGLOBULIN G; INSULIN; MACROGOL;

ANIMAL EXPERIMENT; ARTICLE; CONJUGATION; CONTROLLED STUDY; DRUG HALF LIFE; GEL ELECTROPHORESIS; IMMUNOBLOTTING; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PEGYLATION; PRIORITY JOURNAL; PROTEIN MODIFICATION; RAT; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; ELECTROPHORESIS, POLYACRYLAMIDE GEL; INSULIN; MAGNETIC RESONANCE SPECTROSCOPY; MALE; POLYETHYLENE GLYCOLS; PROTEINS; RATS;

EID: 84860704433     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp200587m     Document Type: Article

References (36)

1. Harris, J. M.; Chess, R. B. Effect of PEGylation on pharmaceuticals Nat. Rev. Drug Discovery 2003, 2, 214-221
2. Kang, J. S.; Deluca, P. P.; Lee, K. C. Emerging PEGylated drugs Expert Opin. Emerg. Drugs 2009, 14, 363-380
3. Pasut, G.; Veronese, F. M. PEGylation for improving the effectiveness of therapeutic biomolecules Drugs Today (Barcelona) 2009, 45, 687-695
4. Veronese, F. M.; Harris, J. M. Peptide and protein PEGylation III: advances in chemistry and clinical applications Adv. Drug Delivery Rev. 2008, 60, 1-2
5. Hu, X.; Olivier, K.; Polack, E.; Crossman, M.; Zokowski, K.; Gronke, R. S.; Parker, S.; Li, Z.; Nestorov, I.; Baker, D. P.; Clarke, J.; Subramanyam, M. In vivo pharmacology and toxicology evaluation of polyethylene glycol-conjugated interferon beta-1a J. Pharmacol. Exp. Ther. 2011, 338, 984-996
6. Ishida, T.; Tagami, T.; Uehara, Y.; Moriyoshi, N.; Kiwada, H. Anti-PEG IgM production by siRNA encapsulated in a PEGylated lipid nanocarrier is dependent on the sequence of the siRNA J. Controlled Release 2011, 151, 149-154
7. Armstrong, J. K.; Hempel, G.; Koling, S.; Chan, L. S.; Fisher, T.; Meiselman, H. J.; Garratty, G. Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients Cancer 2007, 110, 103-111
8. Ganson, N. J.; Kelly, S. J.; Scarlett, E.; Sundy, J. S.; Hershfield, M. S. Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase Arthritis Res. Ther. 2006, 8, R12
9. Graham, M. L. PEGASPARAGINASE: a review of clinical studies Adv. Drug Delivery Rev. 2003, 55, 1293-1302
10. Kinstler, O.; Molineux, G.; Treuheit, M.; Ladd, D.; Gegg, C. Mono-N-terminal poly(ethylene glycol)-protein conjugates Adv. Drug Delivery Rev. 2002, 54, 477-485
11. Bagal, D.; Zhang, H.; Schnier, P. D. Gas-phase proton-transfer chemistry coupled with TOF mass spectrometry and ion mobility-MS for the facile analysis of poly(ethylene glycols) and PEGylated polypeptide conjugates Anal. Chem. 2008, 80, 2408-2418
12. Modi, M. W.; Fulton, J. S.; Buckmann, D. K.; Wright, T. L.; Moore, D. J. Clearance of PEGylated (40 kDa) interferon alfa-2a (PEGASYS) is primarily hepatic Hepatology 2000, 32, 371A
13. Parton, T.; King, L.; van Asperen, J.; Heywood, S.; Nesbitt, A. Investigation of the distribution and elimination of the PEG component of certolizumab pegol in rats Am. J. Gastroenterol. 2008, 103, S431-S432
14. Kurfurst, M. M. Detection and molecular weight determination of polyethylene glycol-modified hirudin by staining after sodium dodecyl sulfate-polyacrylamide gel electrophoresis Anal. Biochem. 1992, 200, 244-248
15. Bailon, P.; Palleroni, A.; Schaffer, C. A.; Spence, C. L.; Fung, W. J.; Porter, J. E.; Ehrlich, G. K.; Pan, W.; Xu, Z. X.; Modi, M. W.; Farid, A.; Berthold, W.; Graves, M. Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C Bioconjugate Chem. 2001, 12, 195-202
16. Tsai, N. M.; Cheng, T. L.; Roffler, S. R. Sensitive measurement of polyethylene glycol-modified proteins BioTechniques 2001, 30, 396-402
17. Wunderlich, D. A.; Macdougall, M.; Mierz, D. V.; Toth, J. G.; Buckholz, T. M.; Lumb, K. J.; Vasavada, H. Generation and characterization of a monoclonal IgG antibody to polyethylene glycol Hybridoma (Larchmont) 2007, 26, 168-172
18. Bovey, F. A.; Mirau, P. A. NMR of Polymers; Academic Press: San Diego, 1996.
19. Kellner, K.; Tessmar, J.; Milz, S.; Angele, P.; Nerlich, M.; Schulz, M. B.; Blunk, T.; Gopferich, A. PEGylation does not impair insulin efficacy in three-dimensional cartilage culture: an investigation toward biomimetic polymers Tissue Eng. 2004, 10, 429-440
20. Luo, Y.; Zhang, R. In Real-time monitoring of PEGylation by NMR spectroscopy, Abstracts of Papers, 230th ACS National Meeting, Washington, DC, Aug 28-Sept 1, 2005; BIOL- 169.
21. Dhalluin, C.; Ross, A.; Huber, W.; Gerber, P.; Brugger, D.; Gsell, B.; Senn, H. Structural, kinetic, and thermodynamic analysis of the binding of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers to the extracellular domain of the receptor IFNAR2 Bioconjugate Chem. 2005, 16, 518-527
22. The EyeTech Study Group. Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina 2002, 22, 143-152.
23. Tanaka, K.; Waki, H.; Ido, Y.; Akita, S.; Yoshida, Y.; Yoshida, T. Protein and polymer analyses up to m/z 100 000 by laser ionization time-of-flight mass spectrometry Rapid Commun. Mass Spectrom. 1988, 2, 151-153
24. Webster, R.; Xie, R.; Didier, E.; Finn, R.; Finnessy, J.; Edgington, A.; Walker, D. PEGylation of somatropin (recombinant human growth hormone): impact on its clearance in humans Xenobiotica 2008, 38, 1340-1351
25. 1H-NMR spectrometry method for quality control of Aloe vera products J. AOAC Int. 2010, 93, 842-848
26. Webster, L.; Blonsky, E. R.; Matz, P.; Levinsky, D.; Martz, R.; Dhar, S.; Neumann, T.; Eldon, M.; Patrick, T. Efficacy, safety and pharmacokinetics of oral NKTR-118 in patients with opioid-induced constipation: results of a randomized, double-blind, placebo-controlled phase 2 study Am. J. Gastroenterology 2009, 104, S174-S174
27. Antonian, L.; Burton, K.; Goodin, R.; Bentley, M.; Eldon, M. A. PEGylation governs the disposition and metabolism of irinotecan following administration of a novel PEG-irinotecan conjugate Eur. J. Cancer (Suppl.) 2007, 5, 115-115
28. Bendele, A.; Seely, J.; Richey, C.; Sennello, G.; Shopp, G. Short communication: renal tubular vacuolation in animals treated with polyethylene-glycol-conjugated proteins Toxicol. Sci. 1998, 42, 152-157
29. Abuchowski, A.; McCoy, J. R.; Palczuk, N. C.; van Es, T.; Davis, F. F. Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase J. Biol. Chem. 1977, 252, 3582-3586
30. Abuchowski, A.; Vanes, T.; Palczuk, N. C.; Davis, F. F. Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol J. Biol. Chem. 1977, 252, 3578-3581
31. Singh, S. K. Impact of product-related factors on immunogenicity of biotherapeutics J. Pharm. Sci. 2011, 100, 354-387
32. Caliceti, P.; Veronese, F. M. Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates Adv. Drug Delivery Rev. 2003, 55, 1261-1277
33. Armstrong, J. K. The occurrence, induction, specificity and potential effect of antibodies against poly(ethylene glycol). In Pegylated protein drugs: Basic science and clinical applications; Veronese, F. M., Ed.; Birkhauser-Verlag: Basel, 2009; pp 147-168.
34. de Kort, M.; Gianotten, B.; Wisse, J. A.; Bos, E. S.; Eppink, M. H.; Mattaar, E.; Vogel, G. M.; Dokter, W. H.; Honing, M.; Vonsovic, S.; Smit, M. J.; Wijkmans, J. C.; van Boeckel, C. A. Conjugation of ATIII-binding pentasaccharides to extend the half-life of proteins: long-acting insulin Chem. Med. Chem. 2008, 3, 1189-1193
35. Alden, C. L.; Frith, C. H. Urinary system. In Handbook of Toxicology and Pathology; Haschek, W. M.; Rousseaux, C. G., Eds.; Academic Press: New York, 1991; pp 339-341.
36. Webster, R.; Elliott, V.; Park, B. K.; Walker, D.; Hankin, M.; Taupin, P. PEG and PEG conjugates toxicity: towards an understanding of the toxicity of PEG and its relevance to PEGylated biologicals. In Pegylated Protein Drugs: Basic Science and Clinical Applications; Parnham, M. J.; Bruinvels, J., Eds.; Birkhauser-Verlag: Basel, 2009; pp 127-146.